

Racotumomab

| | |
|------------------|---|
| Cat. No.: | HY-P99254 |
| CAS No.: | 946832-34-4 |
| Target: | Others |
| Pathway: | Others |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |

BIOLOGICAL ACTIVITY

| | | | | | | | | | | |
|--------------------|---|--|---------------|---|---------|--|-----------------|-------------------------------|---------|-----------------------|
| Description | <p>Racotumomab (Anti-Human NGcGM3 Recombinant Antibody) is an anti-idiotypic monoclonal antibody (MAb). Racotumomab reacts to Neu-glycolyl (NeuGc)-containing gangliosides, sulfatides, and other antigens expressed in tumors. Racotumomab is an active anticancer agent for lung cancer^{[1][2][3]}.</p> | | | | | | | | | |
| In Vitro | <p>Racotumomab induces a specific humoral and cellular immune response against the NeuGcGM3 ganglioside present in tumor cells, stimulating the cell death^[4]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> | | | | | | | | | |
| In Vivo | <p>Racotumomab (50 µg/dose, i.p.) together with Keyhole limpet hemocyanin (KLH) inhibits tumor growth in F3II cell (s.c.) mammary tumor mice model^[2]. Racotumomab (50 µg/dose, s.c.) together with Pemetrexed (100 mg/kg) is highly effective against lung nodules in 3LL cell (s.c.) mice xenograft^[3]. Racotumomab (50-200 µg/dose, s.c.) shows no significant antitumor effect in 3LL cell (s.c.) mice xenograft^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>3LL cell (s.c.) mice xenograft^[3]</td> </tr> <tr> <td>Dosage:</td> <td>50 µg/dose, together with Pemetrexed (100 mg/kg)</td> </tr> <tr> <td>Administration:</td> <td>Subcutaneous injection (s.c.)</td> </tr> <tr> <td>Result:</td> <td>Reduced lung nodules.</td> </tr> </table> | | Animal Model: | 3LL cell (s.c.) mice xenograft ^[3] | Dosage: | 50 µg/dose, together with Pemetrexed (100 mg/kg) | Administration: | Subcutaneous injection (s.c.) | Result: | Reduced lung nodules. |
| Animal Model: | 3LL cell (s.c.) mice xenograft ^[3] | | | | | | | | | |
| Dosage: | 50 µg/dose, together with Pemetrexed (100 mg/kg) | | | | | | | | | |
| Administration: | Subcutaneous injection (s.c.) | | | | | | | | | |
| Result: | Reduced lung nodules. | | | | | | | | | |

REFERENCES

- [1]. Vázquez AM, et al. Racotumomab: an anti-idiotypic vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data. *Front Oncol.* 2012 Oct 23;2:150.
- [2]. Gajdosik Z. Racotumomab - a novel anti-idiotypic monoclonal antibody vaccine for the treatment of cancer. *Drugs Today (Barc).* 2014 Apr;50(4):301-7.
- [3]. Segatori VI, et al. Preclinical evaluation of racotumomab, an anti-idiotypic monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer. *Front Oncol.* 2012 Nov 8;2:160.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA